{
    "abstractText": "School of Nursing, Fudan University, Shanghai, China Fudan University Centre for Evidencebased Nursing: A Joanna Briggs Institute Centre of Excellence, Fudan University, Shanghai, China School of Public Health, Fudan University, Shanghai, China The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong, China The Joanna Briggs Institute, University of Adelaide, Adelaide, South Australia, Australia",
    "authors": [
        {
            "affiliations": [],
            "name": "Zheng Zhu"
        },
        {
            "affiliations": [],
            "name": "Weijie Xing"
        },
        {
            "affiliations": [],
            "name": "Huan Wen"
        },
        {
            "affiliations": [],
            "name": "Yanling Sun"
        },
        {
            "affiliations": [],
            "name": "Winnie K W So"
        },
        {
            "affiliations": [],
            "name": "Lucylynn Lizarondo"
        },
        {
            "affiliations": [],
            "name": "Jian Peng"
        },
        {
            "affiliations": [],
            "name": "Yan Hu"
        }
    ],
    "id": "SP:3db7cad12d49c6ccf9634be5fcf82debd6a198c6",
    "references": [
        {
            "authors": [
                "Bosland MC"
            ],
            "title": "Global health and cancer",
            "venue": "Lancet",
            "year": 2019
        },
        {
            "authors": [
                "JA de Souza",
                "N. Wong Y"
            ],
            "title": "Financial distress in cancer patients",
            "venue": "J Med Person 2013;11:73\u20137",
            "year": 2013
        },
        {
            "authors": [
                "AB Mariotto",
                "KR Yabroff",
                "Y Shao"
            ],
            "title": "Projections of the cost of cancer care in the United States: 2010- 2020",
            "venue": "J Natl Cancer Inst 2011;103:117\u201328",
            "year": 2011
        },
        {
            "authors": [
                "Group ACTION Study",
                "S Jan",
                "M Kimman"
            ],
            "title": "Financial catastrophe, treatment discontinuation and death associated with surgically operable cancer in south- east Asia: results from the action study. Surgery 2015;157:971\u201382",
            "year": 2015
        },
        {
            "authors": [
                "SY Zafar",
                "S. Yousuf Zafar"
            ],
            "title": "Financial toxicity of cancer care: it's time to intervene",
            "venue": "J Natl Cancer Inst 2016;108:djv370",
            "year": 2016
        },
        {
            "authors": [
                "PM Carrera",
                "HM Kantarjian",
                "VS. Blinder"
            ],
            "title": "The financial burden and distress of patients with cancer: understanding and stepping- up action on the financial toxicity of cancer treatment",
            "venue": "CA Cancer J Clin 2018;68:153\u201365",
            "year": 2018
        },
        {
            "authors": [
                "J Witte",
                "K Mehlis",
                "B Surmann"
            ],
            "title": "Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications",
            "venue": "Ann Oncol 2019;30:1061\u201370",
            "year": 2019
        },
        {
            "authors": [
                "Head BA",
                "Faul AC"
            ],
            "title": "Development and validation of a scale to measure socioeconomic well- being in persons with cancer",
            "venue": "J Support Oncol 2008;6:183\u201392",
            "year": 2008
        },
        {
            "authors": [
                "P Wright",
                "AB Smith",
                "A Keding"
            ],
            "title": "The social difficulties inventory (SDI): development of subscales and scoring guidance for staff",
            "venue": "Psychooncology",
            "year": 2011
        },
        {
            "authors": [
                "JL Malin",
                "C Ko",
                "JZ Ayanian"
            ],
            "title": "Understanding cancer patients' experience and outcomes: development and pilot study of the cancer care outcomes research and surveillance patient survey. Support Care Cancer 2006;14:837\u201348",
            "year": 2006
        },
        {
            "authors": [
                "C Ripamonti",
                "R Leporati",
                "G De Feo"
            ],
            "title": "Italian version of the edmonton symptom assessment system (ESAS)- total care (TC): development and psychometric validation in patients undergoing cancer treatment or follow- up. Support Care Cancer 2022;30:1923\u201333",
            "year": 1923
        },
        {
            "authors": [
                "JM Salsman",
                "SC Danhauer",
                "JB Moore"
            ],
            "title": "Systematic review of financial burden assessment in cancer: evaluation of measures and utility among adolescents and young adults and caregivers. Cancer 2021;127:1739\u201348",
            "year": 2021
        },
        {
            "authors": [
                "CAC Prinsen",
                "LB Mokkink",
                "LM Bouter"
            ],
            "title": "COSMIN guideline for systematic reviews of patient- reported outcome measures",
            "venue": "Qual Life Res",
            "year": 2018
        },
        {
            "authors": [
                "MJ Page",
                "JE McKenzie",
                "PM Bossuyt"
            ],
            "title": "The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71",
            "year": 2021
        },
        {
            "authors": [
                "NE Avis",
                "KW Smith",
                "S McGraw"
            ],
            "title": "Assessing quality of life in adult cancer survivors (QLACS)",
            "venue": "Qual Life Res",
            "year": 2005
        },
        {
            "authors": [
                "MA Dar",
                "R Chauhan",
                "K Murti"
            ],
            "title": "Development and validation of subjective financial distress questionnaire (SFDQ): a patient reported outcome measure for assessment of financial toxicity among radiation oncology patients",
            "venue": "Front Oncol 2022;11:819313",
            "year": 1931
        },
        {
            "authors": [
                "JA de Souza",
                "BJ Yap",
                "K Wroblewski"
            ],
            "title": "Measuring financial toxicity as a clinically relevant patient- reported outcome: the validation of the comprehensive score for financial toxicity (cost)",
            "venue": "Cancer 2017;123:476\u201384",
            "year": 2017
        },
        {
            "authors": [
                "K Durber",
                "GK Halkett",
                "M McMullen"
            ],
            "title": "Measuring financial toxicity in Australian cancer patients - validation of the comprehensive score for financial toxicity (FACT COST) measuring financial toxicity in Australian cancer patients",
            "venue": "Asia Pac J Clin Oncol 2021;17:377\u201387",
            "year": 2021
        },
        {
            "authors": [
                "C Harley",
                "S Pini",
                "L Kenyon"
            ],
            "title": "Evaluating the experiences and support needs of people living with chronic cancer: development and initial validation of the chronic cancer experiences questionnaire (CCEQ)",
            "venue": "BMJ Support Palliat Care 2019;9:e15",
            "year": 2019
        },
        {
            "authors": [
                "K Hueniken",
                "CM Douglas",
                "AR Jethwa"
            ],
            "title": "Measuring financial toxicity incurred after treatment of head and neck cancer: development and validation of the financial index of toxicity",
            "year": 2020
        },
        {
            "authors": [
                "L de Alcantara Nogueira",
                "FJ Koller",
                "L Marcondes"
            ],
            "title": "Validation of the comprehensive score for financial toxicity for Brazilian culture",
            "venue": "Ecancermedicalscience",
            "year": 2020
        },
        {
            "authors": [
                "CI Ripamonti",
                "F Chiesi",
                "P Di Pede"
            ],
            "title": "The validation of the Italian version of the comprehensive score for financial toxicity (cost)",
            "venue": "Support Care Cancer 2020;28:4477\u201385",
            "year": 2020
        },
        {
            "authors": [
                "SP Sharif",
                "OF Sim",
                "M. Moshtagh"
            ],
            "title": "Psychometric evaluation of the comprehensive score for financial toxicity scale among iranian cancer patients",
            "venue": "Research Square",
            "year": 2020
        },
        {
            "authors": [
                "V Shilling",
                "R Starkings",
                "V Jenkins"
            ],
            "title": "Development and validation of the patient roles and responsibilities scale in cancer patients",
            "venue": "Qual Life Res",
            "year": 2018
        },
        {
            "authors": [
                "D Tremblay",
                "TG Poder",
                "M Vasiliadis H"
            ],
            "title": "Translation and cultural adaptation of the patient self- administered financial effects (P- SAFE) questionnaire to assess the financial burden of cancer in Frenchspeaking patients",
            "venue": "Healthcare",
            "year": 2020
        },
        {
            "authors": [
                "CM Veenstra",
                "SE Regenbogen",
                "ST Hawley"
            ],
            "title": "A composite measure of personal financial burden among patients with stage III colorectal cancer",
            "venue": "Med Care 2014;52:957\u201362",
            "year": 2014
        },
        {
            "authors": [
                "EP Wright",
                "M Kiely",
                "C Johnston"
            ],
            "title": "Development and evaluation of an instrument to assess social difficulties in routine oncology practice",
            "venue": "Qual Life Res",
            "year": 2005
        },
        {
            "authors": [
                "H Li"
            ],
            "title": "The comprehensive score for financial toxicity in China: validation and responsiveness",
            "venue": "J Pain Symptom Manage 2021;61:1297\u2013304",
            "year": 2021
        },
        {
            "authors": [
                "L Zhao",
                "K Portier",
                "K Stein"
            ],
            "title": "Exploratory factor analysis of the cancer problems in living scale: a report from the American cancer society's studies of cancer survivors",
            "venue": "J Pain Symptom Manage 2009;37:676\u201386",
            "year": 2009
        },
        {
            "authors": [
                "F De Lorenzo",
                "K Apostolidis",
                "F Florindi"
            ],
            "title": "Improving European policy to support cancer survivors",
            "venue": "J Cancer Policy",
            "year": 2018
        },
        {
            "authors": [
                "CC Philip",
                "A Mathew",
                "MJ. John"
            ],
            "title": "Cancer care: challenges in the developing world",
            "venue": "Cancer Res Stat Treat 2018;1:58",
            "year": 2018
        },
        {
            "authors": [
                "Coleman JS"
            ],
            "title": "Foundations of social theory",
            "venue": "Harvard university press,",
            "year": 1994
        },
        {
            "authors": [
                "K Bergeron",
                "S Abdi",
                "K DeCorby"
            ],
            "title": "Theories, models and frameworks used in capacity building interventions relevant to public health: a systematic review",
            "venue": "BMC Public Health 2017;17:914",
            "year": 2017
        },
        {
            "authors": [
                "A. Miller"
            ],
            "title": "Returning to work after head and neck cancer",
            "venue": "Curr Opin Otolaryngol Head Neck Surg",
            "year": 2020
        },
        {
            "authors": [
                "M Giuliani",
                "J Papadakos",
                "M Broadhurst"
            ],
            "title": "The prevalence and determinants of return to work in head and neck cancer survivors",
            "venue": "Support Care Cancer 2019;27:539\u201346",
            "year": 2019
        },
        {
            "authors": [
                "CS Dewa",
                "L Trojanowski",
                "SJ Tamminga"
            ],
            "title": "Work- Related experiences of head and neck cancer survivors: an exploratory and descriptive qualitative study",
            "venue": "Disabil Rehabil 2018;40:1252\u20138",
            "year": 2018
        },
        {
            "authors": [
                "Z Zhu",
                "W Xing",
                "X Zhang"
            ],
            "title": "Cancer survivors' experiences with financial toxicity: a systematic review and meta- synthesis of qualitative studies",
            "venue": "Psychooncology",
            "year": 2020
        },
        {
            "authors": [
                "P Chebli",
                "J Lemus",
                "C Avila"
            ],
            "title": "Multilevel determinants of financial toxicity in breast cancer care: perspectives of healthcare professionals and latina survivors. Support Care Cancer 2020;28:3179\u201388",
            "year": 2020
        },
        {
            "authors": [
                "W Ng C"
            ],
            "title": "Understanding the financial needs following diagnosis of breast cancer in a setting with universal health coverage",
            "venue": "Oncologist",
            "year": 2020
        }
    ],
    "sections": [
        {
            "text": "1Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nTo cite: Zhu\u00a0Z, Xing\u00a0W, Wen\u00a0H, et\u00a0al. Psychometric properties of self- reported financial toxicity measures in cancer survivors: a systematic review. BMJ Open 2022;12:e057215. doi:10.1136/ bmjopen-2021-057215\n\u25ba Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2021-057215).\nReceived 13 September 2021 Accepted 06 June 2022\n1School of Nursing, Fudan University, Shanghai, China 2Fudan University Centre for Evidence- based Nursing: A Joanna Briggs Institute Centre of Excellence, Fudan University, Shanghai, China 3School of Public Health, Fudan University, Shanghai, China 4The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong, China 5The Joanna Briggs Institute, University of Adelaide, Adelaide, South Australia, Australia\nCorrespondence to Dr Weijie Xing; xingweijie@ fudan. edu. cn\n\u00a9 Author(s) (or their employer(s)) 2022. Re- use permitted under CC BY- NC. No commercial re- use. See rights and permissions. Published by BMJ.\nINTRODUCTION The rising cost associated with advancements in cancer treatment and lengthening\nof cancer survivorship poses a significant challenge to survivors, caregivers and public healthcare systems.1 2 Total global spending on cancer medications grows at a compound annual growth rate of 6.5%, growing from US$96 billion in 2013 to US$173 billion in 2020, which is nearly twice the rate of global gross domestic product growth.3\u20135 The majority of cancer survivors in middle- income and low- income countries/regions depend on out- of- pocket payments, which may lead to global inequalities in healthcare expenditures and financial insecurity for vulnerable groups.6 7\nThe term \u2018financial toxicity (FT)\u2019 has been described as the economic effect of cancer treatment in the age of precision medicine.2 8 9 Witte et al described FT as \u2018the patient- reported outcome (PRO) of perceived subjective financial distress resulting from objective financial burden\u2019.10 This concept covers both the objective financial burden and the subjective financial distress that cancer survivors face as a result of high out- of- pocket medical expenses. Regarding the terminology, \u2018financial toxicity\u2019, \u2018financial burden\u2019 and \u2018financial distress\u2019 are often used interchangeably in research and share a similar definition.10 11 In this review, the authors agreed to consistently use the term \u2018financial toxicity\u2019. Financial toxicity is usually measured by PRO measures\nSTRENGTHS AND LIMITATIONS OF THIS STUDY \u21d2 This is the first systematic review that comprehensively summarised the psychometric properties of 21 patient- reported outcome measures (PROMs) evaluating financial toxicity in cancer survivors. \u21d2 The results may provide quantitative evidence for researchers and healthcare professionals to choose PROMs measuring cancer survivors\u2019 financial toxicity in future scientific research and clinical practice. \u21d2 This review only included studies that aimed to evaluate the measurement properties of financial toxicity PROMs.\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\njopen-2021-057215 on 24 June 2022. D ow nloaded from\n2 Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\n(PROMs); choosing a PROM with high validity and reliability is a prerequisite for robust results.\nThere are a few cancer- specific and generic FT PROMs that have been reported and used in different contexts. As one of the recent cancer- specific FT PROMs, the Comprehensive Score for Financial Toxicity (COST) is the most commonly used measure for assessing FT.12 In addition to COST, other cancer- specific measures have been widely used, including the Breast Cancer Finances Survey Inventory,13 Socioeconomic Well- being Scale (SWBS)14 and InCharge Financial Distress/Financial Well- being Scale (InCharge).15 Additionally, validated subscales, such as the Social Difficulties Inventory Cancer Care Outcomes (SDI), the Cancer Care Outcomes Research and Surveillance Consortium patient survey, and Italian version of the Edmonton Symptom Assessment System- Total Care (TC), were also used to evaluate FT.16\u201318 However, existing PROMs vary significantly in their state of development and degree of validation, and many PROMs have not been psychometrically tested.\nA preliminary literature search was conducted in PubMed, PsycINFO (EBSCO), Cochrane Library (Wiley) and Joanna Briggs Institute (Ovid), which revealed that there exist some reviews regarding measures of FT. Witte et al summarised the content of 352 items from 34 studies measuring FT in cancer survivors.10 However, this review did not report the psychometric properties of the included PROMs, and most of the included PROMs were not validated through a scientific process, which made it difficult for readers to choose the best measure from existing PROMs to evaluate the level of FT. Salman et al conducted a systematic review and found eight PROMs and two caregiver- reported measures for assessing financial burden in adolescents and young adults.19 However, this review focused only on PROMs assessing FT in adolescents and young adults with cancer. The psychological properties of FT measures in adult cancer survivors are still unknown.\nThe reproducibility, reliability and accuracy of PROMs are the fundamental premise for achieving robust results. Therefore, it is necessary to summarise the psychometric properties of existing PROMs for future research. However, this information is still lacking. The aim of this systematic review was to summarise the psychometric properties of PROMs for measuring FT in cancer survivors. The review was conducted according to the guidance of the Consensus- Based Standards for the Selection of Health Measurement Instruments (COSMIN) methodology and the Preferred Reporting Items for Systematic Reviews and Meta- Analyses statement.20 21 The protocol of this review was published in BMJ OPEN in 2020.22 The registration number of the protocol in PROSPERO was CRD42021254721."
        },
        {
            "heading": "METHODS Search strategy",
            "text": "First, we conducted a limited search via PubMed to capture keywords from which to develop search strategies\nfor each database. Subsequently, all identified search strategies across databases were performed in PubMed/ MEDLINE, MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), PsycINFO (EBSCO), Web of Science, ProQuest Dissertations and Theses, and Cochrane Library (Wiley). The search time frame was set from database inception to February 2022. To include more studies published in 2021 and 2022, the end date of the search was updated to February 2022.22 In PubMed/Medline, we searched papers in English using MeSH terms ([cancer OR neoplasms] AND [\u201ccancer survivors\u201d OR patient OR survivors] AND \u201ccost of illness\u201d) combined with (cancer OR [patient* OR survivor*] AND [cost OR bill* OR expense OR productivity loss OR \u201cout- of- pocket\u201d OR \u201ceconomic burden\u201d OR \u201cfinancial toxicity\u201d OR \u201cfinancial hardship\u201d OR \u201cfinancial burden\u201d]). The COSMIN measurement properties filter and exclusion filter were also used in the search box. The search strategies for each database are presented in online supplemental appendix 1. Finally, the references of all included studies were manually reviewed to supplement the database search."
        },
        {
            "heading": "Inclusion and exclusion criteria",
            "text": "The inclusion criteria were as follows: (1) studies that reported any PROMs for measuring FT in cancer survivors who were \u226518 years old. If the studies reported results in a population combined with both \u226518 and <18 years old cancer survivors and the majority of survivors were not <18 years old, the studies were also considered; (2) studies that evaluated at least one measurement property; and (3) studies published in English. The exclusion criteria were as follows: (1) studies that were not validation studies and used a PROM only as an outcome measurement; (2) studies that used a PROM as a comparator for another instrument; (3) studies that did not provide empirical data and (4) if a measure was a quality of life PROM and had a domain that assessed FT, we included only the original version of the PROM. If the measure/domain included only one item and reported the measurement property as an independent domain, the measure/domain was also considered."
        },
        {
            "heading": "Study screening and selection",
            "text": "We imported all identified citations by search strategies into Endnote V.X8 (Clarivate Analytics, Pennsylvania, USA). After duplicates were removed, two reviewers (ZZ and WX) independently screened all titles, abstracts and full texts (ZZ and WX) based on the established inclusion and exclusion criteria. Any disagreements were resolved by a third reviewer (YH)."
        },
        {
            "heading": "Quality appraisal",
            "text": "Two reviewers (HW and YS) assessed the methodological quality of the PROM of the included studies by using the COSMIN Risk of Bias Checklist (online supplemental appendix 2).19 The checklist consisted of 10 domains (116 items), including PROM development, content validity, structural validity, internal consistency, cross- cultural\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n3Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\nvalidity, reliability, measurement error, criterion validity, hypothesis testing and responsiveness. Each measurement property was rated as \u2018very good\u2019, \u2018adequate\u2019, \u2018doubtful\u2019 or \u2018inadequate quality\u2019. According to the COSMIN guidelines, the methodological quality of a single study is rated based on the worst score count method. For example, if the lowest rating is \u2018inadequate\u2019 in the PROM development domain, the overall methodological quality of that domain is \u2018inadequate\u2019. The worst score counts method takes into account that inadequate quality items could affect the overall results of the measurement property of each PROM. Any discrepancies were resolved by a third reviewer (ZZ)."
        },
        {
            "heading": "Data extraction",
            "text": "Two reviewers (ZZ and WX) independently extracted data from the included papers, including authors, year of publication, PROM, country/language, study design, target population, sample size, domains, number of items, total score range and main findings. The main findings regarding psychometric properties, including content validity, structural validity, internal consistency, cross- cultural validity, reliability, measurement error, criterion validity, hypothesis testing and responsiveness, were also extracted. Any discrepancies were resolved through discussion between the two reviewers."
        },
        {
            "heading": "Data synthesis",
            "text": "We used the COSMIN criteria to summarise and evaluate the psychometric properties of each study regarding structural validity, internal consistency, reliability, measurement error, hypothesis testing for construct validity, cross- cultural validity/measurement invariance, criterion validity and responsiveness. Each measurement property from each study was rated as sufficient (+), insufficient (\u2212) or indeterminate (?). The criteria for the measurement property rating can be found in online supplemental appendix 2. If the ratings of one psychometric property per study were all sufficient (+) or insufficient (\u2212), the results were pooled, and the overall rating was rated as sufficient (+) or insufficient (\u2212). If the ratings were inconsistent, explanations of inconsistency were explored (eg, different languages). For example, in our review, different language, social, economic and cultural contexts may contribute to inconsistencies in psychometric properties. Our review team (ZZ, WJ, HW and YS) discussed the potential explanations of inconsistency. If the review team regarded the explanation as reasonable, we provided ratings (\u2018+\u2019, \u2018\u2212\u2019 and \u2018?\u2019) in subgroups (eg, language subgroup). If the explanation was not reasonable, the overall rating of this measurement property was rated as inconsistent (\u00b1)."
        },
        {
            "heading": "Assessing certainty of evidence",
            "text": "We used a modified Grading of Recommendations Assessment, Development and Evaluation system to assess the certainty of evidence.19 Each piece of evidence was graded for risk of bias, inconsistency, imprecision and\nindirectness. The instructions for downgrading for risk of bias, inconsistency, imprecision and indirectness are shown in Appendix II. Four reviewers (ZZ, WJ, HW and YS) independently assessed the grade. Any discrepancies were resolved by discussion."
        },
        {
            "heading": "Patient and public involvement",
            "text": "No patients or the public were directly involved in the development of the research question, selection of the outcome measures, design and implementation of the study, or interpretation of the results."
        },
        {
            "heading": "RESULTS Literature search",
            "text": "Figure 1 shows the process of literature screening and selection. A total of 9399 articles were identified via databases. Six articles were found by additional supplementary searches. After duplications were removed, a total of 11 731 articles were retained, 11 669 articles were deleted after reading the title and abstract, and 39 were deleted after full- text reading. Finally, a total of 23 articles (21 PROMs) were eligible for inclusion in this study.12 14 16 23\u201342"
        },
        {
            "heading": "Study description",
            "text": "Table 1 shows the characteristics of the included studies. All included studies were published from 2005 to 2022. Eight studies were conducted in the USA,12 14 23 27 30 37 39 41 four in the UK,16 29 35 38 two in Canada31 36 and two in China (mainland and Hong Kong),25 39 India26 34 and Italy.33 42 One study was conducted in 12 countries in Europe and North America.22 23 Other studies were conducted in Brazil32 and Iran.34 A total of 12 362 participants were included, ranging from 736 to 590141 per study. The majority of studies assessed FT in multiple types of cancer. Only two studies focused on a single type of cancer, namely, lung, colorectal, or head and neck cancer.31 37\nAmong the 21 PROMs, 7 were FT- related domains of quality of life PROMs and 14 were independent PROMs focusing on FT. All PROMs were validated in cancer survivors. Fifteen PROMs were in English,12 14 16 23 25\u201331 35 37 38 40\u201342 and two were in Chinese.24 39 Other languages included French,36 Portuguese,32 Italian,33 42 Hindi25 26 and Persian.34 The number of items evaluating FT ranged from 340 to 23.36 The French version of the Patient SelfAdministered Financial Effects Questionnaire (P- SAFE) did not report the total score range of the whole PROM.36"
        },
        {
            "heading": "Quality assessment",
            "text": ""
        },
        {
            "heading": "Methodological quality assessment",
            "text": "Table 2 shows the methodological quality of the 23 included studies by using the COSMIN checklist. In the PROM development domain, only one study was rated as adequate,42 three studies were rated as doubt12 24 27 29 and the others were rated as inadequate. Two studies reported adequate information in testing the relevance, comprehensiveness and comprehensibility of PROMs.12 27 29 One study reported adequate\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n4 Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\nrelevance and comprehensiveness.42 Among all studies, the most reported domain was internal consistency, except one study.36 Limited information could be retrieved on cross- cultural validity (3 studies),31 32 36 criterion validity (6 studies),16 23 33 35 38 40 reliability (10 studies),12 16 24 27 28 33 35 38\u201340 42 and responsiveness (2 studies).31 39 No data were identified as measurement error."
        },
        {
            "heading": "Measurement property assessment",
            "text": "Table 3 shows the quality of the psychometric properties retrieved from 21 PROMs. Only the Persian version of the COST- v2 and Subjective Financial Distress Questionnaire (SFDQ) were rated as \u2018+\u2019 in structural\nvalidity.26 34 There were 17 PROMs rated as \u2018+\u2019 in internal consistency.12 14 16 23 24 26\u201329 31 32 34 35 37\u201339 41 42 Eight PROMs were rated as \u2018+\u2019\u201d in reliability.12 24 26\u201329 31 35 Ten PROMs were rated as \u2018+\u2019 in hypothesis testing.12 14 23 24 27\u201331 33 35 39 Limited information was retrieved on cross- cultural validity (two PROMs),32 36 criterion validity (six PROMs),16 24 33 35 38 40 and responsiveness (two PROMs).31 39 No PROMs reported data on measurement error."
        },
        {
            "heading": "Certainty of evidence",
            "text": "Table 4 shows the certainty of evidence for each measurement property. Among all included PROMs, the COST showed the best psychometric properties compared with other measures. The COST and its\nFigure 1 PRISMA flow chat of selection process. PRISMA, Preferred Reporting Items for Systematic Reviews and MetaAnalyses.\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n5Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\nTa b\nle 1\nO\nve rv\nie w\no f t\nhe in\ncl ud\ned s\ntu d\nie s\nA ut\nho r\n(y ea\nr) , c\no un\ntr y\nP R\nO M\nC o\nun tr\ny La\nng ua\ng e(\ns) o\nf P\nR O\nM S\ntu d\ny d\nes ig\nn Ta\nrg et\np o\np ul\nat io\nn S\nam p\nle s\niz e\nM ea\nsu re\nm en\nt d\no m\nai n\nN o\no f\nit em\ns To\nta l s\nco re\nr an\ng e\nA vi\ns2 3\n20 05\nQ LA\nC S\nfi na\nnc ia l p ro b le m s d om ai\nn U\nS A\nE ng\nlis h\nD ev\nel op\nm en\nt an\nd\nva lid\nat io\nn st\nud y\nA ge\n: 7 1.\n4\u00b1 11\n.5 y\nea rs\nM al\ne: 4 2% C an ce r ty\np e:\nB re\nas t,\nb la\nd d\ner , h\nea d\nan\nd n\nec k,\ng yn\nec ol\nog ic\n, p ro\nst at\ne,\nco lo\nre ct\nal c\nan ce\nr\n24 2\nO ne\nd om\nai n\nre ga\nrd in g fin an ci al p ro b le m\ns 4\n4\u2013 28\nC ha\nn2 4\n20 21\nC O\nS T-\nv2 , T\nra d\niti on\nal\nC hi\nne se\nv er\nsi on\nH on\ng K\non g\nTr ad\niti on\nal C\nhi ne\nse Va\nlid at\nio n\nst ud\ny A\nge : 5\n9. 9\u00b1\n11 .1\ny ea rs M al e: 3 5. 3% C an ce r ty p e: B re as t,\ng yn\nae co\nlo gi\nca l,\nhe ad\na nd\nn ec\nk, g\nas tr\nic a\nnd\nco lo\nre ct\nal , g\nen ito\nur in\nar y,\nlu ng , ha em at ol og ic al , s ki n, b on e an d\ns of t tis su e, b ra in a nd c en tr al n er vo us sy st em c an ce r an d o th er s\n64 0\nN o\nsu b\nd om\nai n\n12 0\u2013\n44\nD ar\n25 2\n02 1\nC O\nS T-\nv1 , I\nnd ia\nve\nrs io\nn In\nd ia\nH in\nd i o\nr E\nng lis\nh Va\nlid at\nio n\nst ud\ny A\nge : 4\n9. 5\u00b1\n16 .8\ny ea rs M al e: 8 2. 8% C an ce r ty p e: T on gu e,\ng in\ngi va\nl b uc\nca l\nsu lc\nus , b\nuc ca\nl m uc\nos a,\ns up\nra gl\not tic\nla\nry nx\n, h yp\nop ha\nry nx\n, p ar\not id\na nd\not\nhe rs\n29 N\no su\nb d\nom ai\nn 11\n0\u2013 44\nD ar\n25 2\n02 1\nS FD\nQ In\nd ia\nIn d\nia n\nor E\nng lis\nh D\nev el\nop m\nen t\nan d\nva\nlid at\nio n\nst ud\ny A\nge : 1\n8% \u20135\n9 68\n.3 %\n; \u2265 60\n3 10\n.7 %\nM al\ne: 8\n5. 9%\nC an\nce r\nty p\ne: h\nea d\na nd\nn ec\nk ca\nnc er\n14 2\nFi ve\nd om\nai ns\n: fi na\nnc ia l re so ur ce s; fi na nc ia l sp en d in g; p sy ch os oc ia l af fe ct ; c op in g ca re an d c op in g lif es ty le s; su p p or t se ek in g\n14 0\u2013\n28\nd e\nA lc\nan ta\nra\nN og\nue ira\n32 2\n02 0\nC O\nS T-\nv1 , B\nra zi\nlia n\nve rs\nio n\nB ra\nzi l\nB ra\nzi lia\nn P\nor tu\ngu es\ne Va\nlid at\nio n\nst ud\ny M\nea n\nag e:\n5 6\nye ar s M al e: 4 0. 5% C an ce r ty p e: N ot s p\nec ifi\nc\n12 6\nN o\nsu b\nd om\nai n\n11 0\u2013\n44\nD e\nS ou\nza 12\n2 01 4 D e S ou za 27 2 01 7\nC O\nS T-\nv1 U\nS A\nE ng\nlis h\nD ev\nel op\nm en t st ud y an d va lid at io n st ud\ny\nA ge\n: 5 8.\n4\u00b1 11\n.5 y\nea rs\nM al\ne: 4\n1. 6%\nC an\nce r\nty p\ne: N\not s\np ec\nifi ed\n(d ia\ngn os\nis\nof A\nJC C\ns ta\nge IV\nc an\nce r)\n23 3\nN o\nsu b\nd om\nai n\n11 0\u2013\n44\nD ur\nb er\n28 2\n02 1\nC O\nS T-\nv1 A\nus tr\nal ia\nE ng\nlis h\nVa lid\nat io\nn st\nud y\nA ge\n: \u2264 50\ny ea\nrs 2\n3% ; 5\n1\u2013 64\ny ea\nrs\n30 %\n; \u2265 65\ny ea\nrs 4 8% M al e: 4 6% C an ce r ty p e: T ho ra\nci c,\nb re\nas t,\nsa\nrc om\na, s\nki n,\nc en\ntr al\nn er\nvo us\nsy\nst em\n, g yn\nae co\nlo gi\nca l,\nhe ad\nan\nd n\nec k,\nc ol\nor ec\nta l,\nup p\ner\nga st\nro in\nte st\nin al\n, u ro\nlo gi\nca l a\nnd\nm is\nce lla\nne ou\ns ca\nnc er\n25 7\nN o\nsu b\nd om\nai n\n11 0\u2013\n44\nC on\ntin ue\nd\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n6 Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\nA ut\nho r\n(y ea\nr) , c\no un\ntr y\nP R\nO M\nC o\nun tr\ny La\nng ua\ng e(\ns) o\nf P\nR O\nM S\ntu d\ny d\nes ig\nn Ta\nrg et\np o\np ul\nat io\nn S\nam p\nle s\niz e\nM ea\nsu re\nm en\nt d\no m\nai n\nN o\no f\nit em\ns To\nta l s\nco re\nr an\ng e\nH ar\nle y2\n9 20\n19 C\nC E\nQ fi\nna nc\nia l\nad vi\nce d\nom ai\nn U\nK E\nng lis\nh D\nev el\nop m\nen t\nan d\nva\nlid at\nio n\nst ud\ny P\nilo t\nst ud y: A ge : 6 5 (4\n1- 90\n) y rs\nM al\ne: 4\n8. 5%\nC an\nce r\nty p\ne: B\nr e as\nt, c\nol or\nec ta l/ ga st ro in te st in al , g yn ae co lo gi ca l, p ro st at e an d r en al c an ce r Fi na l s tu d y: A ge : 6 7 (4 1\u2013 88 ) y rs M al e: 5 0. 0% C an ce r ty p e: B re as t, c ol or ec ta l/ ga st ro in te st in al , g yn ae co lo gi ca l, p ro st at e an d r en al c an ce r\n10 3\nfo r\np ilo t st ud y 31 3 fo r fin al st ud y\nO ne\nd om\nai n\nre ga\nrd in g fin an ci al a d vi\nce 5\n5\u2013 25\nH ea\nd 14\n2 00\n8 S\nW B\nS U\nS A\nE ng\nlis h\nD ev\nel op\nm en\nt an\nd\nva lid\nat io\nn st\nud y\nA ge\n: 5 9.\n6\u00b1 12\n.7 y\nea rs\nM al\ne: 3\n5. 7%\nC an\nce r\nty p\ne: B\nre as\nt, m\nel an\nom a,\nhe\nad a\nnd n\nec k,\np ro\nst at\ne, r\nec tu\nm /\nan us\n, c ol\non , e\nnd om\net riu\nm , l\nun g/\ntr ac\nhe al\n/b ro\nnc hu\ns an\nd n\non - H\nod gk\nin \u2019s\nly\nm p\nho m\na\n26 6\nTw o\nd om\nai ns\n: m at\ner ia l an d s oc ia l c ap ita l.\n17 0\u2013\n68\nH ue\nni ke\nn3 1\n20 20\nFI T\nC an\nad a\nE ng\nlis h\nD ev\nel op\nm en\nt an\nd\nva lid\nat io\nn st\nud y\nA ge\n: 6 1.\n6 (2\n5. 5\u2013\n88 .5\n) y rs\nM al\ne: 7\n7. 2%\nC an\nce r\nty p\ne: O\nro p\nha ry\nnx , o\nra l c\nav ity , la ry nx , n as op ha ry nx , h yp op ha ry nx ca nc er s an d o th er s\n43 0\nN o\nsu b\nd om\nai n\n9 0\u2013\n10 0\nR ip\nam on\nti3 3\n20 20\nC O\nS T-\nv2 , I\nta lia n ve rs io\nn Ita\nly Ita\nlia n\nVa lid\nat io\nn st\nud y\nA ge\n: 6 1.\n5\u00b1 12\n.7 y\nea rs\nM al\ne: 5\n2. 5%\nC an\nce r\nty p\ne: B\nre as\nt, lu\nng , c\nol on , ga st ric , h ep at oc el lu la r, en d om et\nria l,\np ro\nst at\ne, s\nar co\nm a,\nb la\nd d\ner , h\nea d\nan\nd n\nec k,\nH od\ngk in\nly m\np ho\nm a,\nn on - H od gk in 's ly m p ho m a, le uk ae m ia , m ye lo m a an d o th er s\n11 8\nN o\nsu b\nd om\nai n\n11 0\u2013\n44\nR iv\na4 2\n20 21\nP R\nO FF\nIT Ita\nly Ita\nlia n\nor E\nng lis\nh D\nev el\nop m\nen t\nan d\nva\nlid at\nio n\nst ud\ny A\nge : 2\n9\u2013 82\ny ea rs M al e: 4 1. 3% C an ce r ty p e: b re\nas t,\nlo w\ner\nga st\nro in\nte st\nin al\nt ra\nct , g\nen ito\nur in\nar y,\nth\nor ac\nic , u\np p\ner g\nas tr\noi nt\nes tin\nal t\nra ct\nan\nd o\nth er\ns\n18 4\nN o\nsu b\nd om\nai n\nS ev\nen\nou tc\nom e\nite m s an d e\nig ht\nd\net er\nm in\nan t\nite m\ns\n0\u2013 10\n0\nS ha\nrif 34\n2 02\n0 C\nO S\nTv2\n, P er\nsi an\nve\nrs io\nn Ir\nan P\ner si\nan Va\nlid at\nio n\nst ud\ny A\nge : 5\n0. 0\u00b1\n14 .3\ny ea rs M al e: 5 1. 0% C an ce r ty p e: N ot s p\nec ifi\nc\n39 8\nN o\nsu b\nd om\nai n\n11 0\u2013\n44\nS hi\nlli ng\n35 2\n01 8\nP R\nR S\nfi na\nnc ia\nl w el\nl-\nb ei\nng d\nom ai\nn U\nK E\nng lis\nh D\nev el\nop m\nen t\nan d\nva\nlid at\nio n\nst ud\ny A\nge : \u2264\n50 y\nea rs\n2 5%\n; 5 1\u2013\n65 y\nea rs\n41\n% ; \u2265\n66 y\nea rs\n3 4%\nM al\ne: 2 3% C an ce r ty\np e:\nb r e\nas t,\ng yn\nae co\nlo gi\nca l,\nlu ng\na nd\nm el\nan om\na ca\nnc er\ns\n13 5\nO ne\nd om\nai n\nre ga\nrd in g fin an ci al w el lb ei\nng 6\n0\u2013 24\nTa b\nle 1\nC\non tin\nue d\nC on\ntin ue\nd\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n7Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\nA ut\nho r\n(y ea\nr) , c\no un\ntr y\nP R\nO M\nC o\nun tr\ny La\nng ua\ng e(\ns) o\nf P\nR O\nM S\ntu d\ny d\nes ig\nn Ta\nrg et\np o\np ul\nat io\nn S\nam p\nle s\niz e\nM ea\nsu re\nm en\nt d\no m\nai n\nN o\no f\nit em\ns To\nta l s\nco re\nr an\ng e\nTr em\nb la\ny3 6\n20 20\nP - S\nA FE\n, F re\nnc h\nVe rs\nio n\nC an\nad a\nFr en\nch C\nro ss\n- a d\nap tio n st ud y\nA ge\n: 5 0\u2013\n59 y\nea rs\n5 7%\n; 6 0\u2013\n69 y\nea rs\n29\n% ; \u2265\n70 y\nea rs\n3 4%\nM al\ne: 1 4% C an ce r ty\np e:\nc ol\nor ec\nta l,\nlu ng\n, b re\nas t\nan d\np ro\nst at\ne ca\nnc er\n.\n7 N\nR 23\nN R\nVe en\nst ra\n37 2\n01 4\nP FB\nU S\nA E\nng lis\nh Va\nlid at\nio n\nst ud\ny A\nge : <\n50 y\nea rs\n1 7%\n; 5 0\u2013\n64 y\nea rs\n37\n% ; 6\n5\u2013 74\ny ea\nrs 2\n3% ; >\n75 y\nea rs\n24 % M\nal e:\n5 3%\nC an\nce r\nty p\ne: S\nta ge\nII I c\nol or\nec ta l ca nc er\n95 6\nN o\nsu b\nd om\nai n\n7 0\u2013\n7\nW rig\nht 38\n2 00\n5 S\nD I-\n21 p\nro vi\nd in\ng fo r th e fa m ily d om ai n\nU K\nE ng\nlis h\nD ev\nel op\nm en\nt an\nd\nva lid\nat io\nn st\nud y\nA ge\n: 5 3.\n8\u00b1 14\n.1 y\nea rs\nM al\ne: N\not s\np ec\nifi c\nC an\nce r\nty p\ne: b\nra in\n, l un\ng ca\nnc er\ns an\nd\not he\nrs\n27 1\nO ne\nd om\nai n\nre ga\nrd in g p ro vi d in g fo r th e fa m ily\n5 0\u2013\n20\nW rig\nht 16\n2 01\n1 S\nD I-\n16 m\non ey\nm\nat te\nrs d\nom ai\nn U\nK E\nng lis\nh D\nev el\nop m\nen t\nan d\nva\nlid at\nio n\nst ud\ny A\nge : 5\n6 (1\n8- 88\n) y rs\nfo r\nm en\n; 5 6\n(2 1-\n88\n) y rs\nfo r\nw om en M al e: 4 8% C an ce r ty p e: b\nr e as\nt, g\nas tr\noi nt\nes tin\nal ,\nha em\nat ol\nog y,\ng yn\nae co\nlo gi\nca l,\nge rm\nc el\nl, he\nad a\nnd n\nec k,\nlu ng , ge ni to ur in ar y an d o th er s\n65 2\nO ne\nd om\nai n\nre ga\nrd in g m on ey m at te rs\n5 0\u2013\n20\nYu 39\n2 02\n1 C\nO S\nTv1\n, S im\np lifi\ned\nC hi\nne se\nv er\nsi on\nM ai\nnl an\nd C\nhi na\nC hi\nne se\nVa lid\nat io\nn st\nud y\nA ge\n: 5 7.\n0\u00b1 9.\n2 ye\nar s\nM al\ne: 4\n5. 7%\nC an\nce r\nty p\ne: lu\nng , s\nto m\nac h,\nco\nlo re\nct al\na nd\nb re\nas t\nca nc\ner\n44 0\nN o\nsu b\nd om\nai n\n11 0\u2013\n44\nZ eb\nra ck\n40 2\n01 0\nIO C\n- C S\nfi na\nnc ia l p ro b le m s d om ai\nn U\nS A\nE ng\nlis h\nVa lid\nat io\nn st\nud y\nA ge\n: 2 6.\n7\u00b1 5.\n3 ye\nar s\nM al\ne: 4\n8. 0%\nC an\nce r\nty p\ne: h\nae m\nat ol\nog ic\nal ,\nb ra\nin a\nnd s\nol id\nt um\nou rs\n/s of\nt tis\nsu e\ntu m\nou rs\n51 9\nO ne\nd om\nai n\nre ga\nrd in g fin an ci al p ro b le m\ns 3\n1\u2013 15\nZ ha\no4 1\n20 09\nC P\nIL S\ne m\np lo\nym en t/ fin an ci al d om ai\nn U\nS A\nE ng\nlis h\nVa lid\nat io\nn st\nud y\nA ge\n: \u2264 55\ny ea\nrs 4\n8. 8%\n; > 55\n5 10\n.2 %\nM al\ne: 4\n1. 6%\nC an\nce r\nty p\ne: b\nre as\nt, p\nro st\nat e,\nco\nlo re\nct al\n, b la\nd d\ner , u\nte rin\ne, k\nid ne\ny,\nlu ng\na nd\no va\nria n\nca nc\ner ; m\nel an\nom a\nof s\nki n;\nn on\n- H od\ngk in\n's ly\nm p\nho m\na,\n59 01\nO ne\nd om\nai n\nre ga\nrd in g em p lo ym en t/ fin an ce\ns 6\n0\u2013 12\nA JC\nC , T\nhe A\nm er\nic an\nJ oi\nnt C\nom m\nitt ee\no n\nC an\nce r;\nC C\nE Q\n, C hr\non ic\nC an\nce r\nE xp\ner ie\nnc es\nQ ue\nst io\nnn ai\nre ; C\nO S\nT, C\nom p\nre he\nns iv\ne S\nco re\nfo r\nFi na\nnc ia\nl T ox\nic ity\n; C P\nIL S\n, C an\nce r\nP ro\nb le\nm s\nin L\niv in\ng S\nca le\n; F IT\n, F in\nan ci\nal In\nd ex\no f T\nox ic\nity ; I\nO C\n- C S\n, I m\np ac\nt of\nC\nan ce\nrC\nhi ld\nho od\nS ur\nvi vo\nrs ; N\nR , n\not r\nep or\nt; P\nFB , P\ner so\nna l F\nin an\nci al\nB ur\nd en\n; P R\nO FF\nIT , P\nat ie\nnt - R\nep or\nte d\nO ut\nco m\ne fo\nr Fi\ngh tin\ng Fi\nna nc\nia l T\nox ic\nity ; P\nR O\nM , P\nat ie\nnt - R\nep or\nte d\nO ut\nco m\ne M\nea su\nre s;\nP R\nR S\n, P at\nie nt\nR ol\nes a\nnd R\nes p\non si\nb ili\ntie s\nS ca\nle ; P - S A FE , P at ie nt S el fA d m in is te re d F in an ci al E ffe ct s q ue st io nn ai re ; Q LA C S , Q ua lit y of L ife in A d ul t C an ce r S ur vi vo rs ; S D I, S oc ia l D iffi cu lti es In ve nt or y C an ce r C ar e O ut co m es ; S FD Q , S ub je ct iv e Fi na nc ia l D is tr es s Q ue st io nn ai re ; S W B S , S oc io ec on\nom ic\nW\nel l-\nb ei\nng S\nca le\n.\nTa b\nle 1\nC\non tin\nue d\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n8 Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\nTa b\nle 2\nM\net ho\nd ol\nog ic\nal q\nua lit\ny as\nse ss\nm en\nt of\nt he\nm ea\nsu re\ns\nA ut\nho r\n(y ea\nr) P\nR O\nM\nM ea\nsu re\nm en\nt p\nro p\ner ty\n: m et\nho d\no lo\ng ic\nal q\nua lit\ny b\ny st\nud y\nP R\nO M\nd\nev el\no p\nm en\nt C\no nt\nen t\nva lid\nit y\nS tr\nuc tu\nra l\nva lid\nit y\nIn te\nrn al\nco\nns is\nte nc\ny C\nro ss\n- c ul\ntu ra l va lid it\ny R\nel ia\nb ili\nty M\nea su\nre m\nen t\ner ro\nr C\nri te\nri o n va lid it\ny H\nyp o\nth es\nis t\nes ti\nng R\nes p\no ns\niv en\nes s\nA vi\ns2 3\n20 05\nQ LA\nC S\nfi na\nnc ia l p ro b le m s d om ai\nn In\nad eq\nua te\nR : N R C 1: N R C 2: N R\nA d\neq ua\nte Ve\nry g\noo d\nN R\nN R\nN R\nA d\neq ua\nte D\nou b\ntf ul\nN R\nC ha\nn2 4\n20 21\nC O\nS T-\nv2 ,\nTr ad\niti on\nal\nC hi\nne se\nv er\nsi on\nD ou\nb tf\nul R\n: D ou\nb tf ul C 1: N R C 2: D ou b\ntf ul\nVe ry\ng oo\nd Ve\nry g\noo d\nN R\nD ou\nb tf\nul N\nR N\nR Ve\nry g\noo d\nN R\nD ar\n25 2\n02 1\nC O\nS T-\nv1 , I\nnd ia\nve\nrs io\nn In\nad eq\nua te\nR : N R C 1: N R C 2: N R\nIn ad\neq ua\nte Ve\nry g\noo d\nN R\nN R\nN R\nN R\nN R\nN R\nD ar\n25 2\n02 1\nS FD\nQ In\nad eq\nua te\nR : A\nd eq\nua te\nC 1:\nN R\nC 2:\nN R\nVe ry\ng oo\nd Ve\nry g\noo d\nN R\nN R\nN R\nN R\nN R\nN R\nd e\nA lc\nan ta\nra\nN og\nue ira\n32\n20 20\nC O\nS T-\nv1 , B\nra zi\nlia n\nve rs\nio n\nIn ad\neq ua\nte R\n: N R\nC 1:\nN R\nC 2:\nN R\nVe ry\ng oo\nd Ve\nry g\noo d\nIn ad\neq ua\nte N\nR N\nR N\nR N\nR N\nR\nD e\nS ou\nza 12\n20 14 D e S\nou za\n27\n20 17\nC O\nS T-\nv1 D\nou b\ntf ul\nR : A\nd eq\nua te\nC 1:\nA d\neq ua te C 2: A d eq ua te\nN R\nVe ry\ng oo\nd N\nR A\nd eq\nua te\nN R\nN R\nVe ry\ng oo\nd N\nR\nD ur\nb er\n28 2\n02 1\nC O\nS T-\nv1 , A\nus tr\nal ia\nve\nrs io\nn In\nad eq\nua te\nR : N R C 1: N R C 2: N R\nN R\nVe ry\ng oo\nd N\nR A\nd eq\nua te\nN R\nN R\nVe ry\ng oo\nd N\nR\nH ar\nle y2\n9 20\n19 C\nC E\nQ fi\nna nc\nia l\nad vi\nce d\nom ai\nn D\nou b\ntf ul\nR : A\nd eq\nua te\nC 1:\nA d\neq ua te C 2: A d eq ua te\nA d\neq ua\nte Ve\nry g\noo d\nN R\nN R\nN R\nN R\nVe ry\ng oo\nd N\nR\nH ea\nd 14\n2 00\n8 S\nW B\nS In\nad eq\nua te\nR : N R C 1: D\nou b t C 2: N R\nVe ry\ng oo\nd Ve\nry g\noo d\nN R\nN R\nN R\nVe ry\ng oo\nd Ve\nry g\noo d\nN R\nH ue\nni ke\nn3 1\n20 20\nFI T\nIn ad\neq ua\nte R\n: N R\nC 1:\nN R\nC 2:\nN R\nA d\neq ua\nte Ve\nry g\noo d\nD ou\nb tf\nul N\nR N\nR N\nR Ve\nry g\noo d\nVe ry\ng oo\nd\nR ip\nam on\nti3 3\n20 20\nC O\nS T-\nv2 , I\nta lia n ve rs io\nn In\nad eq\nua te\nR : N R C 1: N R C 2: N R\nIn ad\neq ua\nte Ve\nry g\noo d\nN R\nIn ad\neq ua\nte N\nR Ve\nry g\noo d\nVe ry\ng oo\nd N\nR\nR iv\na4 2\n20 21\nP R\nO FF\nIT A\nd eq\nua te\nR : A\nd eq\nua te\nC 1:\nA d\neq ua te C 2: N R\nA d\neq ua\nte Ve\nry g\noo d\nN R\nA d\neq ua\nte N\nR N\nR N\nR N\nR\nS ha\nrif 34\n2 02\n0 C\nO S\nTv2\n, P er\nsi an\nve\nrs io\nn In\nad eq\nua te\nR : N R C 1: N R C 2: N R\nVe ry\ng oo\nd Ve\nry g\noo d\nN R\nN R\nN R\nN R\nIn ad\neq ua\nte N\nR\nS hi\nlli ng\n35 2\n01 8\nP R\nR S\nfi na\nnc ia l w el lb ei ng d\nom ai\nn In\nad eq\nua te\nR : N R C 1: N R C 2: N R\nA d\neq ua\nte Ve\nry g\noo d\nN R\nIn ad\neq ua\nte N\nR In\nad eq\nua te\nIn ad\neq ua\nte N\nR\nC on\ntin ue\nd\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n9Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\nA ut\nho r\n(y ea\nr) P\nR O\nM\nM ea\nsu re\nm en\nt p\nro p\ner ty\n: m et\nho d\no lo\ng ic\nal q\nua lit\ny b\ny st\nud y\nP R\nO M\nd\nev el\no p\nm en\nt C\no nt\nen t\nva lid\nit y\nS tr\nuc tu\nra l\nva lid\nit y\nIn te\nrn al\nco\nns is\nte nc\ny C\nro ss\n- c ul\ntu ra l va lid it\ny R\nel ia\nb ili\nty M\nea su\nre m\nen t\ner ro\nr C\nri te\nri o n va lid it\ny H\nyp o\nth es\nis t\nes ti\nng R\nes p\no ns\niv en\nes s\nTr em\nb la\ny3 6\n20 20\nP - S\nA FE\n, F re\nnc h\nVe rs\nio n\nIn ad\neq ua\nte R\n: N R\nC 1:\nN R\nC 2:\nN R\nN R\nN R\nIn ad\neq ua\nte N\nR N\nR N\nR N\nR N\nR\nVe en\nst ra\n37\n20 14\nP FB\nIn ad\neq ua\nte R\n: N R\nC 1:\nN R\nC 2:\nN R\nVe ry\ng oo\nd In\nad eq\nua te\nN R\nN R\nN R\nN R\nN R\nN R\nW rig\nht 38\n2 00\n5 S\nD I-\n21 p\nro vi\nd in g fo r th e fa m ily d om ai n\nIn ad\neq ua\nte R\n: D ou\nb t\nC 1:\nN R\nC 2:\nN R\nVe ry\ng oo\nd Ve\nry g\noo d\nN R\nN R\nN R\nN R\nN R\nN R\nW rig\nht 16\n2 01\n1 S\nD I-\n16 m\non ey\nm\nat te\nrs d\nom ai\nn In\nad eq\nua te\nR : D\nou b t C 1: N R C 2: N R\nVe ry\ng oo\nd Ve\nry g\noo d\nN R\nIn ad\neq ua\nte N\nR In\nad eq\nua te\nN R\nN R\nYu 39\n2 02\n1 C\nO S\nTv1 , S im p lifi ed\nC hi\nne se\nve\nrs io\nn\nIn ad\neq ua\nte R\n: N R\nC 1:\nN R\nC 2:\nN R\nVe ry\ng oo\nd Ve\nry g\noo d\nN R\nVe ry\ng oo\nd N\nR N\nR D\nou b\nt D\nou b\nt\nZ eb\nra ck\n40\n20 10\nIO C\n- C S\nfi na\nnc ia l p ro b le m s d om ai\nn In\nad eq\nua te\nR : N R C 1: N R C 2: D\nou b\nt\nA d\neq ua\nte Ve\nry g\noo d\nN R\nA d\neq ua\nte N\nR In\nad eq\nua te\nVe ry\ng oo\nd N\nR\nZ ha\no4 1\n20 09\nC P\nIL S\nem\np lo\nym en t/ fin an ci al d\nom ai\nn\nIn ad\neq ua\nte R\n: N R\nC 1:\nN R\nC 2:\nN R\nVe ry\ng oo\nd Ve\nry g\noo d\nN R\nN R\nN R\nN R\nVe ry\ng oo\nd N\nR\nC C\nE Q\n, C hr\non ic\nC an\nce r\nE xp\ner ie\nnc es\nQ ue\nst io\nnn ai\nre ; C\nO S\nT, C\nom p\nre he\nns iv\ne S\nco re\nfo r\nFi na\nnc ia\nl T ox\nic ity\n; C P\nIL S\n, C an\nce r\nP ro\nb le\nm s\nin L\niv in\ng S\nca le\n; F IT\n, F in\nan ci\nal In\nd ex\no f T\nox ic\nity ; I\nO C\n- C S\n, I m\np ac\nt of\nC an\nce r-\nC hi\nld ho\nod S\nur vi\nvo rs\n; N A\n, n ot\na p\np lic\nab le ; N R , n ot r ep or t; P FB , P er so na l F in an ci al B ur d en ; P R O FF IT , P at ie nt - R ep or te d O ut co m e fo r Fi gh tin g Fi na nc ia l T ox ic ity ; P R O M , P at ie nt - R ep or te d O ut co m e M ea su re s; P R R S , P at ie nt R ol es a nd R es p on si b ili tie s S ca le ; P - S A FE , P at ie nt S el fA d m in is te\nre d\nFi\nna nc\nia l E\nffe ct\ns q\nue st\nio nn\nai re\n; Q LA\nC S\n, Q ua\nlit y\nof L\nife in\nA d\nul t\nC an\nce r\nS ur\nvi vo\nrs ; S\nD I,\nS oc\nia l D\niffi cu\nlti es\nIn ve\nnt or\ny C\nan ce\nr C\nar e\nO ut\nco m\nes ; S\nFD Q\n, S ub\nje ct\niv e\nFi na\nnc ia\nl D is\ntr es\ns Q\nue st\nio nn\nai re\n; S W\nB S\n, S oc\nio ec\non om\nic W\nel l-\nb ei\nng S\nca le\n.\nTa b\nle 2\nC\non tin\nue d\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n10 Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\nTa b\nle 3\nR\nat in\ng of\nm ea\nsu re\nm en\nt p\nro p\ner tie\ns\nP R\nO M\nA ut\nho r\n(y ea\nr) S\ntr uc\ntu ra\nl v al\nid it\ny In\nte rn\nal c\no ns\nis te\nnc y\nR el\nia b\nili ty\nM ea\nsu re\nm en\nt er\nro r\nH yp\no th\nes is\nt es\nti ng\nC ro\nss - c\nul tu\nra l v\nal id\nit y\nC ri\nte ri\no n\nva lid\nit y\nR es\np o\nns iv\nen es\ns\nC C\nE Q\nfi na\nnc ia l ad vi ce d om ai n\nH ar\nle y2\n9 20\n19 \u2013 (n\no d\nat a)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n71 \u20130\n.8 8)\nN R\nN R\n+ (r =\n0. 35\n\u20130 .3\n9) N\nR N\nR N\nR\nC O\nS T-\nv1 D\ne S\nou za\n12 2\n01 4;\nD e\nS ou\nza 27\n2 01\n7 N\nR + (C\nro nb\nac h\u2019\ns \u03b1=\n0. 92\n) + (IC\nC =\n0. 80\n) N\nR + (r\n= 0.\n20 \u20130\n.4 2)\nN R\nN R\nN R\nC O\nS T-\nv1 ,\nA us\ntr al\nia v\ner si\non D\nur b\ner 28\n2 02\n1 N\nR + (C\nro nb\nac h\u2019\ns \u03b1=\n0. 89\n) + (IC\nC =\n0. 80\n) N\nR + (r\n= -0\n.3 9\u2013\n0. 52\n) N\nR N\nR N\nR\nC O\nS T-\nv1 ,\nB ra\nzi lia\nn ve\nrs io\nn d\ne A\nlc an\nta ra\nN\nog ue\nira 32\n2 02\n0 -\n(R M\nS E\nA =\n1. 20\n) + (C\nro nb\nac h\u2019\ns \u03b1=\n0. 83\n) N\nR N\nR N\nR \u2013 (p\n< 0.\n01 )\nN R\nN R\nC O\nS T-\nv1 , I\nnd ia\nve\nrs io\nn D\nar 25\n2 02\n1 \u2013 (E\nFA : \u03c7\n2 = 60\n.8 2)\n? (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n92 )\nN R\nN R\nN R\nN R\nN R\nN R\nC O\nS T-\nv1\nS im\np lifi\ned\nC hi\nne se\nv er\nsi on\nYu 39\n2 02\n1 \u2013 (C\nFI =\n0. 86 ; S R M R =\n0. 08\n)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n85 \u20130\n.8 8)\n+ (IC C\n= 0.\n85 )\nN R\n+ (r =\n-0 .5\n7\u2013 0.\n88 )\nN R\nN R\n? (n o\ncl ea r hy p ot\nhe si\ns)\nC O\nS T-\nv2 , I\nta lia n ve rs io\nn R\nip am\non ti3\n3 20\n20 ? (C\nFI =\n1. 00 ; R M S E A = 0.\n04 )\n? (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n83 )\n+ (IC C\n= 0.\n79 )\nN R\n+ (r =\n-0 .6\n6\u2013 0.\n15 )\nN R\n+ (\u03b2 =\n\u2212 0.\n55 )\nN R\nC O\nS T-\nv2 , P\ner si\nan\nve rs\nio n\nS ha\nrif 34\n2 02\n0 + (C\nFI =\n0. 97 ; R M S E A = 0.\n07 )\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n89 )\nN R\nN R\n? (n o\ncl ea\nr hy\np ot\nhe si\ns) N\nR N\nR N\nR\nC O\nS T-\nv2 ,\nTr ad\niti on\nal\nC hi\nne se\nv er\nsi on\nC ha\nn2 4\n20 21\n\u2013 (C FI\n= 0.\n91 ;\nR M\nS E\nA =\n0. 15\n)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n86 )\n+ (IC C\n= 0.\n71 )\nN R\n+ (r =\n-0 .4\n6\u2013 0.\n47 )\nN R\nN R\nN R\nC P\nIL S\nem\np lo\nym en t/ fin an ci al d\nom ai\nn\nZ ha\no4 1\n20 09\n\u2013 (E FA\n: n o\nm od\nel\nd at\na)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n78 \u20130\n.9 7)\nN R\nN R\n? (n o\ncl ea\nr hy\np ot\nhe si\ns) N\nR N\nR N\nR\nFI T\nH ue\nni ke\nn3 1\n20 20\n\u2013 (E FA\n: n o\nm od\nel\nd at\na)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n77 )\n+ (IC C\n= 0.\n70 )\nN R\n+ (r =\n0. 26\n\u20130 .6\n1) N\nR N\nR + (r\n= \u2212\n0. 25\n)\nIO C\n- C S\nfi na\nnc ia l p ro b le m s d om ai\nn Z\neb ra\nck 40\n2 01\n0 \u2013 (E\nFA : n\no m\nod el\nd\nat a)\n\u2013 (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n70 \u20130\n.8 6)\n\u2013 (IC C\n\u00a0\u2265 0.\n75 )\nN R\n\u2013 (> 75\n% w\ner e\nno t\nsi gn\nifi ca\nnt )\nN R\n? (n o\nd at\na) N\nR\nP FB\nVe en\nst ra\n37 2\n01 4\n\u2013 (C FA\n: n o\nm od\nel\nd at\na)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n79 )\nN R\nN R\nN R\nN R\nN R\nN R\nP R\nO FF\nIT R\niv a4\n2 20\n21 \u2013 (E\nFA : n\no m\nod el\nd\nat a)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n87 )\n+ (IC C\n= 0.\n80 )\nN R\nN R\nN R\nN R\nN R\nP R\nR S\nfi na\nnc ia l w el lb ei ng d om ai n\nS hi\nlli ng\n35 2\n01 8\n\u2013 (E FA\n: n o\nm od\nel\nd at\na)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n90 )\n+ (IC C\n= 0.\n86 )\nN R\n+ (r =\n-0 .7\n1\u2013 0.\n65 )\nN R\n+ (r =\n\u2212 0.\n65 )\nN R\nP - S\nA FE\n, F re\nnc h\nVe rs\nio n\nTr em\nb la\ny3 6\n20 20\nN R\nN R\nN R\nN R\nN R\n? (n o\nd at\na) N\nR N\nR\nQ LA\nC S\nfi na\nnc ia l p ro b le m s d om ai\nn A\nvi s2\n3 20\n05 \u2013 (C\nFA : n\no m\nod el\nd\nat a)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n72 )\nN R\nN R\n+ (r =\n-0 .5\n7\u2013 0.\n60 )\nN R\n\u2013 (r =\n\u2212 0.\n72 )\nN R\nC on\ntin ue\nd\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n11Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\nseven versions were rated as having high evidence of structural validity, internal consistency, hypothesis testing and criterion validity.12 24 25 27 28 32\u201334 39 The Financial Index of Toxicity (FIT) and Impact of Cancer- Childhood Survivors (IOC- CS) financial problems domain reported data on five properties and were rated on a scale from \u2018very low evidence\u2019 to \u2018high evidence\u2019.31 40"
        },
        {
            "heading": "DISCUSSION",
            "text": "This systematic review identified 21 PROMs and domains of PROMs evaluating FT in cancer survivors, including the COST (original, Brazilian, India, Italian, Persian, Simplified Chinese, Traditional Chinese version), FIT, Personal Financial Burden, P- SAFE, SWBS, Quality of Life in Adult Cancer Survivors (QLACS) financial problems domain, Chronic Cancer Experiences Questionnaire financial advice domain, Patient- Reported Outcome for Fighting Financial Toxicity (PROFFIT), Patient Roles and Responsibilities Scale financial well- being domain, SDI- 21 providing for the family domain, SDI- 16 money matters domain, SFDQ, IOC- CS financial problems domain and Cancer Problems in Living Scale (CPILS) employment/ financial domain. Overall, the COST had a complete development process compared with other PROMs and showed the best psychometric properties, especially in terms of internal consistency, reliability and hypothesis testing. To the best of our knowledge, this is the first systematic review that has summarised the psychometric properties of FT PROMs in cancer survivors and reported the certainty of evidence for each property of PROMs. The results may provide quantitative evidence for researchers and healthcare professionals to choose PROMs measuring cancer survivors\u2019 FT in future scientific research and clinical practice.\nThe results highlighted that the COST (of which we studied both version 1 and version 2) had better psychometric properties than other specific and generic PROMs in terms of internal consistency, reliability and hypothesis testing. The COST could be recommended as the most suitable worldwide available measure for use in research and clinical practice across different contexts. Other systematic reviews have also suggested that the COST is a promising measure from a content perspective.10 11 From a psychometric standpoint, there are a few issues that one must face when evaluating financial toxicity in cancer survivors using the COST. First, caution should be taken when using the COST in different socioeconomic conditions outside the USA. In some countries in Europe or Asia, the majority of medical expenses are covered by social health insurance, and direct out- of- pocket payments are replaced by prepayment from health insurance contributions.43 44 In addition, social security systems can benefit cancer survivors who are not able to work.45 These two socioeconomic factors may affect cancer survivors\u2019 understanding regarding some items related to medical spending and indirect cost. However, few COST P R O M A ut ho r (y ea r) S tr uc tu ra l v al id it y In te rn al c o ns is te nc\ny R\nel ia\nb ili\nty M\nea su\nre m\nen t\ner ro\nr H\nyp o\nth es\nis t\nes ti\nng C\nro ss\n- c ul\ntu ra\nl v al\nid it\ny C\nri te\nri o\nn va\nlid it\ny R\nes p\no ns\niv en\nes s\nS D\nI16\nm on\ney\nm at\nte rs\nd om\nai n\nW rig\nht 16\n2 01\n1 \u2013 (E\nFA : n\no m\nod el\nd\nat a)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n71 \u20130\n.8 2)\nN R\nN R\nN R\nN R\nN R\nN R\nS D\nI21\np ro\nvi d\nin g\nfo r\nth e\nfa m\nily\nd om\nai n\nW rig\nht 38\n2 00\n5 \u2013 (E\nFA : n\no m\nod el\nd\nat a)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n50 \u20130\n.8 6)\n\u2013 (W ei\ngh te\nd\nka p\np a=\n0. 54\n\u20130 .8\n0)\nN R\n\u2013 (3 3%\nw er\ne no t si gn ifi ca nt )\nN R\n? (r =\n\u2212 0.\n72 )\nN R\nS FD\nQ D\nar 25\n2 02\n1 + (C\nFI =\n0. 98 , TL I= 0. 97 , R M S E A =\n0. 04\n5,\nS R\nM R\n= 0.\n01 4)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n85 \u20130\n.8 8)\nN R\nN R\nN R\nN R\nN R\nN R\nS W\nB S\nH ea\nd 14\n2 00\n8 \u2013 (C\nFA : n\no m\nod el\nd\nat a)\n+ (C ro\nnb ac\nh\u2019 s\n\u03b1= 0.\n92 )\nN R\nN R\n+ (r =\n-0 .5\n7\u2013 0.\n60 )\nN R\n+ (r =\n-0 .1\n2\u2013 0.\n03 )\nN R\nC C\nE Q\n, C hr\non ic\nC an\nce r\nE xp\ner ie\nnc es\nQ ue\nst io\nnn ai\nre ; C\nFA , C\non fir\nm at\nor y\nFa ct\nor A\nna ly\nsi s;\nC FI\n, C om\np ar\nat iv\ne Fi\nt In\nd ex\n; C O\nS T,\nC om\np re\nhe ns\niv e\nS co\nre fo\nr Fi\nna nc\nia l T\nox ic\nity ; C\nP IL\nS , C\nan ce\nr P\nro b\nle m\ns in\nL iv\nin g\nS ca\nle ; E\nFA , E\nxp lo\nra to\nry F\nac to\nr A\nna ly\nsi s;\nF IT , Fi na nc ia l I nd ex o f T ox ic ity ; I C C , I nt ra cl as s C or re la tio n C oe ffi ci en t; IO C - C S , I m p ac t of C an ce rC hi ld ho od S ur vi vo rs ; N A , n ot a p p lic ab le ; N R , n ot r ep or t; P FB , P er so na l F in an ci al B ur d en ; P R O FF IT , P at ie nt - R ep or te d O ut co m e fo r Fi gh tin g Fi na nc ia l To xi ci ty ; P R O M , p at ie nt - r ep or te d o ut co m e m ea su re s; P R R S , P at ie nt R ol es a nd R es p on si b ili tie s S ca le ; P - S A FE , P at ie nt S el fA d m in is te re d F in an ci al E ffe ct s q ue st io nn ai re ; Q LA C S , Q ua lit y of L ife in A d ul t C an ce r S ur vi vo rs ; R M S E A , R oo t M ea n S q ua re E rr or o f A p p ro xi m at io n; S D I, S oc ia l D iffi cu lti es In ve nt or y C an ce r C ar e O ut co m es ; S FD Q , S ub je ct iv e Fi na nc ia l D is tr es s Q ue st io nn ai re ; S R M R , S ta nd ar d iz ed R oo t M ea n S q ua re R es id ua l; S W B S , S oc io ec on om ic W el lb ei ng S ca le . Ta b le 3 C on tin ue d\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n12 Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\nTa b\nle 4\nC\ner ta\nin ty\no f e\nvi d\nen ce\no f m\nea su\nre m\nen t\np ro\np er\ntie s\nP R\nO M\nA ut\nho r\n(y ea\nr) S\ntr uc\ntu ra\nl v al\nid it\ny In\nte rn\nal c\no ns\nis te\nnc y\nR el\nia b\nili ty\nM ea\nsu re\nm en\nt er\nro r\nH yp\no th\nes is\nt es\nti ng\nC ro\nss - c\nul tu\nra l v\nal id\nit y\nC ri\nte ri\no n\nva lid\nit y\nR es\np o\nns iv\nen es\ns\nC C\nE Q\nfi na\nnc ia\nl a d\nvi ce\nd\nom ai\nn H\nar le\ny2 9\n20 19\nM od\ner at\ne H\nig h\n\u2013 \u2013\nH ig\nh \u2013\n\u2013 \u2013\nC O\nS T-\nv1 D\ne S\nou za\n12 2\n01 4;\nD e\nS ou\nza 27\n2 01\n7 \u2013\nH ig\nh M\nod er\nat e\n\u2013 H\nig h\n\u2013 \u2013\n\u2013\nC O\nS T-\nv1 , A\nus tr\nal ia\nve\nrs io\nn D\nur b\ner 28\n2 02\n1 \u2013\nH ig\nh M\nod er\nat e\n\u2013 H\nig h\n\u2013 \u2013\n\u2013\nC O\nS T-\nv1 , B\nra zi\nlia n\nve rs\nio n\nd e\nA lc\nan ta\nra\nN og\nue ira\n32 2\n02 0\nH ig\nh H\nig h\n\u2013 \u2013\n\u2013 Ve\nry lo\nw \u2013\n\u2013\nC O\nS T-\nv1 , I\nnd ia\nv er\nsi on\nD ar\n25 2\n02 1\nVe ry\nL ow\nLo w\n\u2013 \u2013\n\u2013 \u2013\n\u2013 \u2013\nC O\nS T-\nv1 , S\nim p\nlifi ed\nC\nhi ne\nse v\ner si\non Yu\n39 2\n02 1\nH ig\nh H\nig h\nH ig\nh \u2013\nLo w\n\u2013 \u2013\nLo w\nC O\nS T-\nv2 , I\nta lia\nn ve\nrs io\nn R\nip am\non ti3\n3 20\n20 Ve\nry lo\nw H\nig h\nVe ry\nlo w\n\u2013 H\nig h\n\u2013 H\nig h\n\u2013\nC O\nS T-\nv2 , P\ner si\nan\nve rs\nio n\nS ha\nrif 34\n2 02\n0 H\nig h\nH ig\nh \u2013\n\u2013 Ve\nry lo\nw \u2013\n\u2013 \u2013\nC O\nS T-\nv2 , T\nra d\niti on\nal\nC hi\nne se\nv er\nsi on\nC ha\nn2 4\n20 21\nH ig\nh H\nig h\nLo w\n\u2013 H\nig h\n\u2013 \u2013\n\u2013\nC P\nIL S\ne m\np lo\nym en t/ fin an ci al d om ai\nn Z\nha o4\n1 20\n09 H\nig h\nH ig\nh \u2013\n\u2013 H\nig h\n\u2013 \u2013\n\u2013\nFI T\nH ue\nni ke\nn3 1\n20 20\nLo w\nM od\ner at\ne Ve\nry L\now \u2013\nM od\ner at\ne \u2013\n\u2013 M\nod er\nat e\nIO C\n- C S\nfi na\nnc ia l p ro b le m s d om ai\nn Z\neb ra\nck 40\n2 01\n0 M\nod er\nat e\nH ig\nh M\nod er\nat e\n\u2013 H\nig h\n\u2013 Ve\nry lo\nw \u2013\nP FB\nVe en\nst ra\n37 2\n01 4\nM od\ner at\ne Ve\nry lo\nw \u2013\n\u2013 \u2013\n\u2013 \u2013\n\u2013\nP R\nO FF\nIT R\niv a4\n2 20\n21 M\nod er\nat e\nH ig\nh M\nod er\nat e\n\u2013 \u2013\n\u2013 \u2013\n\u2013\nP R\nR S\nfi na\nnc ia\nl w el\nl-\nb ei\nng d\nom ai\nn S\nhi lli\nng 35\n2 01\n8 M\nod er\nat e\nH ig\nh Ve\nry lo\nw \u2013\nVe ry\nlo w\n\u2013 Ve\nry lo\nw \u2013\nP - S\nA FE\n, F re\nnc h\nVe rs\nio n\nTr em\nb la\ny3 6\n20 20\n\u2013 \u2013\n\u2013 \u2013\n\u2013 Ve\nry lo\nw \u2013\n\u2013\nQ LA\nC S\nfi na\nnc ia l p ro b le m s d om ai\nn A\nvi s2\n3 20\n05 M\nod er\nat e\nH ig\nh \u2013\n\u2013 Lo\nw \u2013\nM od\ner at\ne \u2013\nS D\nI16\nm on\ney m\nat te\nrs\nd om\nai n\nW rig\nht 16\n2 01\n1 H\nig h\nH ig\nh Ve\nry lo\nw \u2013\n\u2013 \u2013\nVe ry\nlo w\n\u2013\nS D\nI21\np ro\nvi d\nin g\nfo r\nth e\nfa m\nily d\nom ai\nn W\nrig ht\n38 2\n00 5\nH ig\nh H\nig h\n\u2013 \u2013\n\u2013 \u2013\n\u2013 \u2013\nS FD\nQ D\nar 26\n2 02\n2 H\nig h\nH ig\nh \u2013\n\u2013 \u2013\n\u2013 \u2013\n\u2013\nS W\nB S\nH ea\nd 14\n2 00\n8 H\nig h\nH ig\nh \u2013\n\u2013 H\nig h\n\u2013 \u2013\n\u2013\nC C\nE Q\n, C hr\non ic\nC an\nce r\nE xp\ner ie\nnc es\nQ ue\nst io\nnn ai\nre ; C\nO S\nT, C\nom p\nre he\nns iv\ne S\nco re\nfo r\nFi na\nnc ia\nl T ox\nic ity\n; C P\nIL S\n, C an\nce r\nP ro\nb le\nm s\nin L\niv in\ng S\nca le\n; F IT\n, F in\nan ci\nal In\nd ex\no f T\nox ic\nity ; I\nO C\n- C S\n, I m\np ac\nt of\nC an\nce r-\nC hi\nld ho\nod S\nur vi\nvo rs\n; P FB\n, P er\nso na l Fi na nc ia l B ur d en ; P R O M , P at ie nt - R ep or te d O ut co m e M ea su re s; P R O FF IT , P at ie nt - R ep or te d O ut co m e fo r Fi gh tin g Fi na nc ia l T ox ic ity ; P R R S , P at ie nt R ol es a nd R es p on si b ili tie s S ca le ; P - S A FE , P at ie nt S el fA d m in is te re d F in an ci al E ffe ct s q ue st io nn ai re ; Q LA C S , Q ua lit y of L ife in A d ul t C an ce r S ur vi vo rs ; R M S E A , R oo t M ea n S q ua re E rr or o f A p p ro xi m at io n; S D I, S oc ia l D iffi cu lti es In ve nt or y C an ce r C ar e O ut co m es ; S FD Q , S ub je ct iv e Fi na nc ia l D is tr es s Q ue st io nn ai re ; S W B S , S oc io ec on om ic W el lb ei ng S ca le .\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n13Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\nvalidation studies have considered socioeconomic issues, adapted the measure in a local context or provided data on cross- cultural validity. It is recommended that future COST validation studies recruit cancer survivors across multiple social and cultural backgrounds to assess crosscultural measurement invariance.\nSecond, the original construct and item generation for the COST were based on a literature search; thus, the theoretical grounds for the measure are unclear, and the instrument may not capture detailed information related to the construct. Theoretical frameworks and conceptual models are crucial for self- reported measures to capture subtle changes in constructs.46 Although FT is a relatively new concept, certain models can guide item generation in the development of future FT PROMs. Tucker- Seeley and colleagues developed a conceptual model of FT and emphasised three components of financial burden, namely, the material, psychosocial and behavioural domains.47 Head developed SWBS based on James Coleman\u2019s Theory of Social Class; this scale contains 17 items across 3 domains: human capital, material capital and social capital.14 30 48 Witte et al\u2019s systematic review analysed 352 different questions regarding financial spending and found six domains (financial spending, financial resources, psychosocial affect, support seeking, coping care and coping lifestyle) that can represent reactions to subjective financial distress.10 Other theories and models, including the Wreckers theory of financial distress, ecological theory and the functionalist tradition, have also been widely used in cancer survivors.49\u201351 With the increasing number of theoretical studies related to FT, the theoretical grounds for future PROMs need to be clarified.\nIn addition to the COST, two other PROMs, namely, the FIT and the IOC- CS financial problems domains, also provided adequate data on psychometric properties. The FIT is relatively new and has fewer items than the other included measures. This measure was developed by Hueniken et al and has been validated only in survivors with head and neck cancer.31 Head and neck cancer, especially laryngeal and hypopharyngeal cancer, has particularly large impacts on survivors\u2019 daily function (eg, speech and eating) after treatment and affects survivors\u2019 ability to return to work.52 53 Only 32%\u201359% of head and neck cancer survivors return to work after treatment.54 This form of cancer also has short- term and long- term financial consequences for caregivers and their families.55 Therefore, future studies should be aware that the FIT may not be directly applicable to other cancer populations.\nRegarding PROM development, we found that only two PROMs, PROFFIT and SFDQ, were not developed in the context of English- speaking developed countries such as the USA, the UK and Canada. The socioeconomic contexts and healthcare systems in these countries may be significantly different from those in other parts of the world and ultimately lead to a nuance in the perceived causes and consequences of FT. Previous studies have reported that FT is closely related to broad\nsocial determinants of economic circumstances. Factors including healthcare policy, healthcare system, insurance system, specific micro contexts and the level of regional economic development could not only affect the cancer survivors\u2019 perceived level of FT but also determine the origins of FT.56 57 Additionally, cultural factors (eg, a cultural emphasis on saving and a cultural imperative to have a large family) also affect cancer survivors\u2019 perceived financial security and economic burden.58\nPROFFIT, which was developed in 2021 in the Italian context, also reported higher quality PROM development and content validity than other PROMs. We would consider it to be a good FT PROM against the COSMIN criteria if more validation studies were conducted to report a greater effect size of the measurement properties. Therefore, we recommend that researchers use contextspecific measures to assess FT in cancer survivors (eg, using PROFFIT in Italy). Further studies are warranted to develop various FT PROMs based on different social and cultural backgrounds. Worldwide measures, such as COST, should be analysed to determine the differences between social, cultural and economic contexts."
        },
        {
            "heading": "Limitations",
            "text": "We acknowledge that there are some limitations to this study. First, this review included only studies that aimed to evaluate the measurement properties of FT PROMs. Many studies that aimed to explore the level of FT in cancer survivors also reported the reliability and validity of PROMs. Therefore, the PROMs we summarised in this systematic review had higher psychometric quality than other measures that we did not list in this review. Second, we included only studies published in English. Therefore, studies published in other languages were not included, which may affect the conclusion of this review. Third, we included only the original version of the FT domain from PROMs assessing quality of life in cancer survivors, such as the EORTC QLQ- C30 and the QLACS. Over 20 language versions of these PROMs do not provide sufficient details on the FT domain individually."
        },
        {
            "heading": "CONCLUSION",
            "text": "This systematic review summarised the psychometric properties of 20 PROMs evaluating FT in cancer survivors. The findings highlighted that, from a psychometric property perspective, the COST had an adequate PROM development process and showed the best psychometric properties among all examined PROMs, especially in internal consistency, reliability and hypothesis testing; thus, we recommend the COST as the most suitable worldwide available measures for use in research and clinical practice across different contexts. The FIT and the IOC- CS financial problems domain also had adequate psychometric properties. We suggest that PROMs should be selected only after careful consideration of the local socioeconomic context. Future studies are warranted to develop various FT PROMs based on different social and\nP atna). P rotected by copyright. on January 17, 2024 at Indian Institute of T\nechnology P atna (IIT\nhttp://bm jopen.bm j.com /\nB M J O pen: first published as 10.1136/bm jopen-2021-057215 on 24 June 2022. D ow nloaded from\n14 Zhu\u00a0Z, et\u00a0al. BMJ Open 2022;12:e057215. doi:10.1136/bmjopen-2021-057215\nOpen access\ncultural backgrounds and a clear theoretical basis for assessing FT.\nTwitter Lucylynn Lizarondo @lucylizarondo20\nContributors WX took full responsibility for the work, had access to the data, and controlled the decision to publish. ZZ and WX designed the systematic review, conducted data searching, extraction and analysis, assessing the certainty of evidence, and wrote the draft of the manuscript. HW and YS conducted quality appraisal and assessing the certainty of evidence. WKWS, LL, JP and YH provided critical comments. All authors approved the final version of the manuscript. WX is the guarantor.\nFunding This work was supported by National Natural Science Foundation of China (Grant number: 72004034), China Medical Board Open Competition Program (Grant number: 20- 371), Shanghai Pujiang Program (Grant number: 2019PJC017), and Shanghai Soft Science Key Program (Grant number: 20692104800)\nCompeting interests None declared.\nPatient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.\nPatient consent for publication Not applicable.\nProvenance and peer review Not commissioned; externally peer reviewed.\nData availability statement No data are available.\nSupplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer- reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.\nOpen access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non- commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non- commercial. See:\u00a0http://creativecommons.org/licenses/by-nc/4.0/.\nORCID iD Zheng\u00a0Zhu http://orcid.org/0000-0001-9651-8311"
        }
    ],
    "title": "Psychometric properties of self- reported financial toxicity measures in cancer survivors: a systematic review",
    "year": 2022
}